web analytics

Immunovia Interim Report, January-June 2019

“The second quarter 2019 was particularly successful as we hit a key milestone and reached several key objectives as the optimization work was completed. We are continuing to ramp up towards commercializing IMMray™ PanCan-d, our diagnostic test for early detection of pancreatic cancer.

At the beginning of June, we announced excellent results from IMMray™ PanCan-d’s optimization work. This study, performed in collaboration with Prof. Stephen Pereira of the University College of London , is the first ever to achieve such results where pancreatic cancer (PDAC, pancreatic ductal

Source: Immunovia Interim Report, January-June 2019

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.